Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.62 |
| ▸ | CISD1 | Q9NZ45 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 10/20 | 0.34 |
| ▸ | CA2 | P00918 | 10/20 | 0.34 |
| ▸ | CA12 | O43570 | 8/20 | 0.34 |
| ▸ | CA9 | Q16790 | 8/20 | 0.34 |
| ▸ | CA7 | P43166 | 5/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.34 |
| ▸ | CA5A | P35218 | 4/20 | 0.34 |
| ▸ | CA6 | P23280 | 4/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.34 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azosemide SCHEMBL48976 | 0.93 | PDE4D (0.70) | PDE4DPDE3ACISD1POLBCA1 | |
| Azosemide SCHEMBL4421865 | 0.93 | PDE4D (0.70) | PDE4DPDE3ACISD1POLBCA1 | |
| Azosemide SCHEMBL30754398 | 0.93 | PDE4D (0.70) | PDE4DPDE3ACISD1POLBCA1 | |
| Azosemide SCHEMBL8988688 | 0.92 | PDE4D (0.69) | PDE4DPDE3ACISD1POLBCA1 | |
| Azosemide SCHEMBL231405 | 0.84 | PDE4D (0.58) | PDE4DPDE3ACISD1POLBCA1 | |
| Azosemide SCHEMBL230300 | 0.82 | PDE4D (0.57) | PDE4DPDE3ACISD1POLBCA1 | |
| SCHEMBL11929680 | 0.82 | PDE4D (0.55) | PDE4DPDE3ACISD1POLBALDH1A1 | |
| SCHEMBL12522802 | 0.82 | PDE4D (0.55) | PDE4DPDE3ACISD1ALDH1A1PTGS2 | |
| SCHEMBL10281116 | 0.81 | PDE4D (0.54) | PDE4DPDE3ACISD1POLBALDH1A1 | |
| SCHEMBL14513929 | 0.81 | PDE4D (0.53) | PDE4DPDE3ACISD1POLBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240009153-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS, INC. | 2024-01-11 | — | — | US | disclosed |
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2019-05-23 | — | — | US | disclosed |
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2017-08-31 | — | — | US | disclosed |
| US-9682928-B2 | Bumetanide analogs, compositions and methods of use | NEUROPRO THERAPEUTICS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS INC. | 2015-03-19 | — | — | US | disclosed |
| US-20120004225-A1 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| EP-2389371-A2 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | Neurotherapeutics Pharma, Inc. (US) | 2011-11-30 | — | — | EP | disclosed |
| WO-2010085352-A2 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240009153-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | PDE4D 654/4885PDE3A 519/4885CISD1 3650/4885 |
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | PDE4D 597/4885PDE3A 441/4885CISD1 3887/4885 |
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A11, SLC6A13 | PDE4D 855/4885PDE3A 416/4885CISD1 3822/4885 |
| US-20120004225-A1 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | ABCG2, ABCB1, TRPV1 | PDE4D 694/4885PDE3A 574/4885CISD1 1251/4885 |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | PDE4D 819/4885PDE3A 770/4885CISD1 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.